Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PHGDH | O43175 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2326970 | 0.88 | TFPI2 (0.68) | ALDH1A1TFPI2KMT2AMEN1TSHR | |
| SCHEMBL19341777 | 0.88 | TFPI2 (0.68) | ALDH1A1TFPI2KMT2AMEN1TSHR | |
| SCHEMBL9880151 | 0.88 | TFPI2 (0.68) | ALDH1A1TFPI2KMT2AMEN1TSHR | |
| SCHEMBL2331589 | 0.85 | TFPI2 (0.52) | ALDH1A1TFPI2KMT2ALMNAMEN1 | |
| SCHEMBL12443568 | 0.83 | TFPI2 (0.50) | ALDH1A1TFPI2KMT2ALMNAMEN1 | |
| SCHEMBL12390225 | 0.79 | TFPI2 (0.50) | TFPI2KMT2ASMN1; SMN2 | |
| SCHEMBL5080239 | 0.76 | KMT2A (0.78) | ALDH1A1KMT2ALMNAMEN1TSHR | |
| SCHEMBL19172946 | 0.76 | HSD11B1 (0.60) | ALDH1A1KMT2ALMNAMEN1TSHR | |
| SCHEMBL9880152 | 0.75 | ALDH1A1 (0.54) | ALDH1A1KMT2ALMNAMEN1TSHR | |
| SCHEMBL9881182 | 0.74 | TFPI2 (0.71) | ALDH1A1TFPI2LMNATSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270736-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270736-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | HCCS, OXA1L, OTC | ALDH1A1 358/4885TFPI2 4858/4885KMT2A 1912/4885 |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | HCCS, VHL, OXA1L | ALDH1A1 473/4885TFPI2 4843/4885KMT2A 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.